Anti-CD45 monoclonal-antibody BC8-I-131

Drug Profile

Anti-CD45 monoclonal-antibody BC8-I-131

Alternative Names: 131-I-labeled anti-CD45 antibody; 131-I-labeled BC8 antibody; 131I-BC8 (anti-CD45) antibody - Actinium Pharmaceuticals; Anti-CD45 monoclonal antibody-I-131; BC 8; BC8-I-131 construct; Iomab-B

Latest Information Update: 20 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Fred Hutchinson Cancer Research Center
  • Developer Actinium Pharmaceuticals; Fred Hutchinson Cancer Research Center
  • Class Antineoplastics; Immunoconjugates; Immunotherapies; Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action CD45 antigen inhibitors; Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Phase III Acute myeloid leukaemia
  • Phase II Acute lymphoblastic leukaemia; Myelodysplastic syndromes
  • Phase I Hodgkin's disease; Non-Hodgkin's lymphoma

Most Recent Events

  • 13 Nov 2017 Actinium Pharmaceuticals announces intention to submit MAA to EMA for Acute myeloid leukaemia
  • 13 Nov 2017 Actinium Pharmaceuticals announces intention to submit NDA to US FDA for Acute myeloid leukaemia
  • 15 Jun 2017 Anti-CD45 monoclonal-antibody BC8-I-131 is available for licensing in Europe, USA as of 15 June 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top